MyRisk with RiskScore ® is a powerful tool that evaluates 48 genes to help healthcare providers identify their patients’ risk of developing 11 different types of hereditary cancer.

MyRisk ® Hereditary Cancer Test is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.

Genetic insights today mean smarter healthcare decisions tomorrow. Understanding the hereditary risk of cancer or a cancer’s aggressiveness can help prevent the onset or progression of disease, creating better outcomes and more peace of mind.

Myriad’s MyRisk Hereditary Cancer Test gives you a clearer understanding of your individual risk for 11 types of hereditary cancers. By looking at your genes, MyRisk can identify whether you carry a genetic mutation that is associated with an increased risk for hereditary cancer. The MyRisk Hereditary Cancer Test Positive

The MyRisk Hereditary Cancer Panel helps you determine your patient’s hereditary cancer risk, focusing on 11 common cancers. Discover how MyRisk can help you.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease.

Hereditary cancer testing is a type of genetic test that can help your healthcare provider find out if you’re at higher risk for developing cancer, due to a genetic mutation that may have been passed down through your family.

If you have a genetic mutation found in a hereditary cancer syndrome, your risk of developing a second cancer are significantly increased. Below are examples of the HBOC and Lynch genes. Lifetime Cancer Risk for people with an identified hereditary cancer risk*

Nov 18, 2022 · Clinical Genetic Test offered by Myriad Genetics, Inc. for conditions (32): EGFR-related lung cancer; AXIN2-related attenuated familial adenomatous polyposis; BAP1-related tumor predisposition syndrome; ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...